Guardant Health
GH
$157.58
-3.43%
Guardant Health, Inc. is a precision oncology company specializing in liquid biopsy tests for cancer detection and monitoring, with key products including Guardant360 for genomic profiling, Reveal for molecular residual disease, and Shield for colorectal cancer screening. As a market leader in the liquid biopsy space, the company has established a strong competitive position through its FDA-approved tests and extensive clinical validation. The current investor narrative centers on the company's recent FDA approval for an expanded liquid biopsy test, which is expected to drive growth in its oncology franchise, alongside the commercial ramp of its Shield screening test. Additionally, the stock has seen a massive rally, up over 295% in the past year, reflecting optimism about its growth prospects and market expansion, though concerns about profitability and competition remain.…
GH
Guardant Health
$157.58
Related headlines
Investment Opinion: Should I buy GH Today?
Rating: Buy. Guardant Health is a high-growth precision oncology leader with a strong product portfolio and recent FDA approval, but its valuation and profitability concerns warrant a cautious approach. The consensus Strong Buy rating and average target of $173.17 support a positive outlook, with 6.9% upside from current levels.
Sign up to view all
GH 12-Month Price Forecast
The AI model assesses a bullish stance with medium confidence, driven by strong revenue acceleration and a favorable regulatory environment. However, the high valuation and persistent losses temper confidence. The model would upgrade to high confidence if the company achieves positive operating income or if Shield shows rapid adoption. Conversely, a downgrade to neutral would occur if revenue growth falls below 30% or if the stock's PS ratio exceeds 15x.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Guardant Health's 12-month outlook, with a consensus price target around $188.96 and implied upside of +19.9% versus the current price.
Average Target
$188.96
0 analysts
Implied Upside
+19.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$105 - $225
Analyst target range
Guardant Health is covered by 24 analysts, with a consensus recommendation of 'Strong Buy' (mean rating of 1.32 on a 1-5 scale, where 1 is Strong Buy). The average price target is $173.17, implying a 6.9% upside from the current price of $161.99. The analyst sentiment is overwhelmingly bullish, with no sell ratings and a majority of buy/overweight ratings, reflecting confidence in the company's growth trajectory and recent FDA approval. The target price range spans from $90.00 (low) to $215.00 (high), indicating a wide dispersion of expectations. The high target of $215.00 suggests potential for 32.7% upside, likely assuming successful commercialization of Shield and continued market share gains, while the low target of $90.00 implies a 44.4% downside, possibly pricing in competitive pressures or slower-than-expected adoption. Recent ratings actions have been uniformly positive, with firms like Canaccord Genuity, Morgan Stanley, and Citigroup maintaining or reiterating buy ratings in July 2026, reinforcing the bullish outlook. The wide spread between low and high targets highlights the uncertainty inherent in the high-growth diagnostics space, but the overall consensus leans strongly positive.
Bulls vs Bears: GH Investment Factors
Guardant Health presents a compelling growth story with accelerating revenue, a recent FDA approval, and strong analyst support, but it remains deeply unprofitable and trades at a premium valuation. The bull case is supported by tangible catalysts and market leadership, while the bear case hinges on valuation risk and the path to profitability. Currently, the bull side has stronger evidence given the revenue acceleration and FDA approval, but the key tension is whether the company can convert its growth into sustainable profitability before investor patience wanes. If revenue growth continues at 40%+ and margins improve, the stock could justify its premium; otherwise, a de-rating is likely.
Bullish
- Revenue growth accelerating to 48.3% YoY: Q1 2026 revenue of $301.7M grew 48.3% YoY, up from 39.3% in Q4 2025 and 14.3% in Q3 2025, showing strong momentum across Oncology ($205.0M) and Screening ($41.6M) segments. This acceleration indicates successful commercial execution and market adoption.
- FDA approval for expanded liquid biopsy test: The recent FDA approval for an expanded liquid biopsy test (announced May 20, 2026) solidifies Guardant's market leadership and creates a new growth catalyst. This approval is expected to drive adoption of Guardant360 and support the oncology franchise.
- Strong analyst consensus with 6.9% upside: With a Strong Buy consensus (mean rating 1.32) from 24 analysts and an average price target of $173.17, the stock has implied upside of 6.9% from $161.99. The high target of $215 suggests 32.7% potential, reflecting optimism about Shield's commercial ramp.
- Gross margin expansion to 65.2%: Gross margin improved to 65.2% in Q1 2026 from 64.6% in Q4 2025 and 63.3% a year ago, indicating scale benefits and pricing power. This trend supports the path to profitability as revenue grows.
Bearish
- Persistent losses and negative free cash flow: Q1 2026 net loss was $112.1M with a net margin of -37.2%, and free cash flow was -$71.2M. The company has not achieved profitability, and the negative operating margin of -40.2% shows heavy spending on R&D and sales & marketing.
- Valuation premium to industry at 422%: The trailing PS ratio of 13.04x is 422% above the industry average of 2.5x. Even the forward PS of 3.47x (based on estimated revenue of $3.69B) implies a significant premium, which could compress if growth disappoints.
- Negative shareholders' equity and high debt-to-equity: Debt-to-equity is -17.22 due to negative shareholders' equity, a red flag for financial stability. The company relies on external financing, as seen in the $612M net cash from financing in Q1 2026, which could dilute shareholders.
- Stock overextended after 295% rally: The stock is up 295% in the past year, trading near the high end of its 52-week range (91.7% of range). This rapid appreciation may have priced in near-term catalysts, leaving limited upside and higher pullback risk.
GH Technical Analysis
Guardant Health's stock is in a powerful uptrend, with a 1-year price change of +295.29%, significantly outperforming the S&P 500's +18.19% over the same period. The current price of $161.99 sits near the upper end of its 52-week range, at approximately 91.7% of the range (calculated as (161.99 - 40.35) / (176.58 - 40.35) * 100), indicating strong momentum and investor confidence, though it also suggests the stock may be overextended in the short term. The stock has more than quadrupled from its 52-week low of $40.35, reflecting a remarkable recovery and sustained buying interest.
Beta
1.59
1.59x market volatility
Max Drawdown
-33.0%
Largest decline past year
52-Week Range
$48-$177
Price range past year
Annual Return
+253.4%
Cumulative gain past year
| Period | GH Return | S&P 500 |
|---|---|---|
| 1m | -3.3% | +2.8% |
| 3m | +64.7% | +4.2% |
| 6m | +54.7% | +11.3% |
| 1y | +253.4% | +21.5% |
| ytd | +54.9% | +12.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GH Fundamental Analysis
Guardant Health's revenue is growing rapidly, with Q1 2026 revenue of $301.7 million, up 48.3% year-over-year, accelerating from the 39.3% growth in Q4 2025 and 14.3% in Q3 2025. The growth is driven by strong performance in its Oncology segment ($205.0 million) and Screening segment ($41.6 million), with Biopharma & Data contributing $53.0 million. Despite the revenue surge, the company remains unprofitable, with a net loss of $112.1 million in Q1 2026, though the net margin improved to -37.2% from -45.7% in Q4 2025, indicating progress toward profitability. Gross margin is solid at 65.2%, up from 64.6% in Q4 2025, reflecting scale benefits, but operating margin remains deeply negative at -40.2%, driven by heavy investments in R&D ($91.0 million) and sales & marketing ($169.1 million). The company's balance sheet shows a current ratio of 4.84, indicating strong liquidity, but a negative debt-to-equity ratio of -17.22 due to negative shareholders' equity, which is typical for high-growth biotech firms with accumulated losses. Free cash flow was -$71.2 million in Q1 2026, improving from -$41.9 million in Q4 2025, but the company still relies on external financing, as evidenced by the $612.0 million net change in cash from financing activities in Q1 2026.
Quarterly Revenue
$301665000.0B
2026-03
Revenue YoY Growth
+48.3%
YoY Comparison
Gross Margin
65.2%
Latest Quarter
Free Cash Flow
$-224832000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GH Overvalued?
Given the company's negative net income, the price-to-sales (PS) ratio is the most appropriate valuation metric, and at 13.04x trailing sales, it reflects the market's high growth expectations. The forward PS ratio, based on estimated revenue of $3.69 billion, would be approximately 3.47x, implying a significant premium for future growth. Compared to the industry average PS ratio of 2.5x, Guardant trades at a 422% premium, which is justified by its superior revenue growth (48.3% YoY) and leadership in the liquid biopsy market. Historically, the stock's PS ratio has ranged from 14.6x to 133.8x over the past five years, and the current 13.04x is near the lower end of that range, suggesting that despite the recent rally, the valuation is not stretched relative to its own history, potentially offering room for further upside if growth continues.
PE
-30.8x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-37.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant: Guardant posted a net loss of $112.1M in Q1 2026, with a net margin of -37.2%, and free cash flow of -$71.2M. The company's negative shareholders' equity (debt-to-equity of -17.22) and reliance on external financing (net $612M from financing in Q1) highlight a fragile balance sheet. While the current ratio of 4.84 provides liquidity, the ongoing cash burn of ~$225M TTM could necessitate future dilution or debt, pressuring the stock. Additionally, operating margin of -40.2% shows heavy spending on R&D and sales & marketing, which may not yield returns if growth slows.